Short answer: On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee separately voted 8–6, with one abstention, to recommend adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List. The recommendations are non-binding. They are not FDA approval, and they do not automatically place either substance on the list. [1] [2]
Last verified: July 23, 2026, 2:49 p.m. ET. Both tallies were verified from the official webcast. FDA had not yet posted a written tally on the meeting page when this article was finalized.
The BPC-157 FDA status in 2026 is easy to misstate because several regulatory questions are being compressed into one headline. A committee recommendation, placement on a statutory list, FDA approval, and a laboratory supplier’s research-use-only position are separate matters. Each has a different decision-maker and a different legal effect.
The July 23 votes changed one layer: the advisory committee recommended that FDA add two identified BPC-157 bulk drug substances to the section 503A list. FDA staff had recommended the opposite after reviewing the available record. The agency—not the committee—will decide what happens next. [1] [5]
BPC-157 FDA status 2026: what changed and what did not
| Question | Status after the July 23 meeting | What that means |
|---|---|---|
| Committee recommendation for BPC-157 free base | Changed: 8 yes, 6 no, 1 abstention | The committee recommended list placement; the vote is advisory. [1] [2] |
| Committee recommendation for BPC-157 acetate | Changed: 8 yes, 6 no, 1 abstention | A separate advisory recommendation was made for the acetate form. [2] |
| FDA approval | Did not change | No BPC-157 drug product became FDA-approved. Compounded drugs are not FDA-approved. [4] [5] |
| Placement on the 503A Bulks List | Not final | A committee vote does not itself amend the list; FDA addresses substances through its list-development and rulemaking process. [3] |
| FDA staff’s scientific assessment | Did not change at the meeting | The briefing document still records the staff proposal not to add either form based on the available evidence. [5] |
| Secra Labs’ position | Did not change | Secra remains an independent research-material supplier, not a section 503A compounding pharmacy. Its BPC-157 material remains strictly research-use only. |
This table is the most useful guardrail against three common headline errors. The committee did not “approve” BPC-157, did not make a final change to the 503A list, and did not newly “legalize” or “ban” the substance. It answered two recommendation questions presented by FDA. [1] [3]
What did the FDA BPC-157 vote cover?
The Pharmacy Compounding Advisory Committee considered whether BPC-157 free base and BPC-157 acetate should be included on the 503A Bulks List. FDA’s meeting agenda identified ulcerative colitis as the use evaluated for both substances. The nominations had previously been withdrawn, but FDA elected to evaluate both forms on its own initiative. [1] [5]
Section 503A describes conditions under which qualifying preparation by state-licensed pharmacists or physicians can receive exemptions from specified provisions of the Federal Food, Drug, and Cosmetic Act. When no applicable USP/NF monograph exists and the substance is not a component of an approved drug, appearing on the 503A Bulks List can satisfy one of the conditions governing use of that bulk substance. Other statutory conditions still apply. [3] [4]
That is a list-eligibility question, not a drug-approval application. FDA states that compounded drugs do not undergo the agency’s premarket review for safety, effectiveness, and quality. The committee vote therefore cannot support a claim that BPC-157 is FDA-approved. [4]
Why were BPC-157 free base and acetate voted on separately?
The two tallies were not duplicate votes on one undifferentiated item. FDA’s briefing describes BPC-157 acetate as a salt of the BPC-157 free-base peptide. It also explains that free bases and salt forms are distinct bulk drug substances because their chemical structures and physical, chemical, pharmacokinetic, or pharmacodynamic characteristics can differ. Those differences can affect properties such as solubility, stability, and impurity profiles. [5]
This form-specific distinction matters beyond terminology. FDA said the submitted nominations and certificates of analysis did not consistently identify which BPC-157 form was being discussed. The agency therefore evaluated the free base and acetate separately and asked the committee to vote on each one. [5]
For laboratory procurement, the broader lesson is documentation-led: a common compound name is not a substitute for a clearly identified material form. Identity records, lot references, analytical methods, and form-specific documentation help keep unlike materials from being treated as interchangeable.
Why did FDA staff recommend against adding either form?
Before the meeting, FDA staff concluded that the available record weighed against placing either BPC-157 free base or BPC-157 acetate on the 503A Bulks List. The committee ultimately reached a different recommendation, but the staff analysis remains important because it shows where FDA found the record incomplete. [5]
FDA’s concerns fell into four connected areas:
- Characterization and identity: FDA cited inconsistent naming and inadequate information about critical quality attributes needed to establish identity, purity, and quality for the proposed compounded products. [5]
- Impurities and manufacturing: The agency identified unresolved questions involving peptide-related impurities, aggregates, microbial quality, and sensitivity to manufacturing and finished-product conditions. [5] [6]
- Effectiveness evidence: FDA found the evidence insufficient to support the evaluated use. Its review described a single small exploratory trial with limited detail and noted that the broader nonclinical record did not resolve biological plausibility or mechanism questions. [5]
- Safety information: FDA said the available safety information was insufficient to characterize the safety profile for the proposed forms and routes, while reports in the adverse-event database were too limited and confounded to establish causality. [5] [6]
An evidence gap is not proof of a specific outcome in either direction. It means the record did not give FDA enough reliable, form-specific information to resolve the question under the criteria it was applying.
Evidence-gap matrix: what FDA evaluated and why uncertainty remained
| Review area | What the FDA record contained | Why uncertainty remained |
|---|---|---|
| Substance identity | Information for both free base and acetate, including submitted certificates of analysis | Naming, form identification, and critical-quality-attribute information were inconsistent or incomplete. [5] |
| Purity and impurity control | Purity results and some analytical information | FDA found gaps involving specified impurities, aggregates, microbial quality, and other product-relevant attributes. [5] |
| Historical compounding use | Literature and market information reviewed by FDA | Available information was too limited, and sources often did not clearly identify free base versus acetate. [5] |
| Effectiveness for the evaluated use | A small exploratory trial plus nonclinical literature | Limited study detail, unresolved mechanisms, and insufficient form- and use-specific evidence prevented a supported conclusion. [5] |
| Safety and exposure | Limited published human information, nonclinical literature, and adverse-event reports | The record was too narrow to characterize the safety profile; adverse reports could not establish causality. [5] |
| Finished-product quality | General peptide-quality considerations and proposed product formats | Formulation, storage, aggregation, and peptide-related impurities could change the finished-product risk profile, but product-specific information was incomplete. [5] [6] |
This matrix also explains how a favorable advisory vote can coexist with a negative staff recommendation. Committee members weigh the record and may disagree about how the statutory factors should be balanced. Their recommendation becomes an input to FDA, not a replacement for agency action. [1]
What the FDA BPC-157 vote did not do
The vote did not approve a BPC-157 drug. FDA approval follows a separate premarket review pathway, and compounded drugs are not FDA-approved. [4]
The vote did not immediately add either form to the 503A Bulks List. FDA explains that it develops and updates the list through evaluation and notice-and-comment rulemaking. [3]
The vote did not endorse a supplier or product. The committee reviewed identified bulk drug substances in a section 503A context. It did not evaluate Secra Labs, Secra’s BPC-157 research material, or its analytical documentation. [1]
Finally, the vote did not change Secra Labs’ research-use-only controls. The article reports a public regulatory development; it does not expand the intended scope of any Secra material.
What happens next for the BPC-157 503A Bulks List review?
FDA can consider the committee’s votes, the discussion, the staff analysis, and public comments as it determines the next regulatory step. Advisory committees provide recommendations, but the final decision rests with the agency. FDA’s current 503A page says substances are addressed on a rolling basis through notice-and-comment rulemaking. [1] [3]
Until FDA publishes subsequent action, the most precise description is: the committee recommended list placement; final FDA action remains pending. Secra Labs will update this article if FDA posts a written vote record or changes the status of either BPC-157 form.
What the BPC-157 FDA status 2026 means for research laboratories
For research laboratories, the immediate value of the meeting is regulatory clarity—not a change in research scope. The committee’s question concerned section 503A compounding. Secra Labs is an independent research-material supplier and is not a 503A pharmacy.
Secra’s BPC-157 remains limited to qualified in-vitro laboratory research and analytical work. Laboratories evaluating research material should continue to review the identified material, lot-specific documentation, analytical information, and storage details relevant to their workflow. The advisory vote does not replace those controls.
Learn more about Secra’s documentation-first approach on the About Secra Labs page.
Frequently asked questions
Is BPC-157 FDA approved in 2026?
No. The July 23 committee votes were recommendations about whether two BPC-157 bulk drug substances should be added to the 503A Bulks List. They were not drug-approval votes. FDA also states that compounded drugs are not FDA-approved. [1] [4]
Did the FDA BPC-157 vote legalize or ban BPC-157?
Neither description is accurate. The committee recommended adding the free base and acetate to a list used in the section 503A compounding framework. The votes did not themselves amend the list, approve a drug, or create a new ban. [2] [3]
What is the 503A Bulks List?
It is an FDA list of bulk drug substances that can satisfy one condition for compounding under section 503A when no applicable USP/NF monograph exists and the substance is not a component of an FDA-approved drug. Inclusion is not FDA approval, and section 503A’s other conditions still apply. [3] [4]
Why were there two BPC-157 votes?
FDA treats BPC-157 free base and BPC-157 acetate as distinct bulk drug substances. A free base and its salt can have different structures and material properties, so the committee answered a separate listing question for each form. [5]
What happens after the advisory committee vote?
FDA reviews the recommendation together with the full record and determines the agency’s next action. The recommendation is influential but not binding. A subsequent change to the 503A Bulks List requires FDA action through the applicable process. [1] [3]
Does the vote change Secra Labs’ research-use-only position?
No. Secra Labs remains a research-material supplier, not a 503A compounding pharmacy. The BPC-157 research material remains strictly limited to qualified in-vitro laboratory research and analytical use.
Primary sources
- FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting
- FDA official July 23 webcast
- FDA: Bulk Drug Substances Used in Compounding Under Section 503A
- FDA: Human Drug Compounding Laws
- FDA briefing document: Evaluation of BPC-157 Free Base and BPC-157 Acetate
- FDA: Certain Bulk Drug Substances That May Present Significant Safety Risks
Editorial notice: This article is a source-based regulatory explainer, not legal or medical advice. Final publication requires Secra Labs owner/compliance review. Update the verification timestamp and if FDA publishes a written vote record or subsequent action.